MetaCap

Kiora Pharmaceuticals (KPRX) vs Xenetic Biosciences (XBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xenetic Biosciences is the larger company by market cap ($3.3 million vs $3.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KPRX-71.53%XBIO-36.65%
+5%-35%-75%
Oct 7, 20261 yearNov 20, 2026
KPRX-71.65%XBIO-34.27%
+4%-36%-75%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KPRX versus XBIO key metrics
MetricKPRXXBIO
Share price$0.7202$1.40
Market cap$3.19M$3.28M
1-day change-12.28%-9.09%
YTD return-63.44%—
1-year return-61.49%—
5-year return-99.87%—
EPS (TTM)$-2.72$-1.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$2.98M
Revenue growth (YoY)-100.00%+19.04%
Net income (latest FY)$-10.84M$-2.68M
Operating margin—-95.23%
Net margin—-90.07%
52-week high$2.91$4.94
52-week low$0.72$1.25
Distance from 52-week high-75.25%-71.65%
Analyst consensusnone—
Avg. price target upside+1566.20%—
Average volume35.23K73.30K
Shares outstanding4.42M2.34M
Employees132
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Xenetic Biosciences grew revenue faster in its latest fiscal year (+19.04% vs -100.00%).

About Kiora Pharmaceuticals

KPRX stock →

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Xenetic Biosciences

XBIO stock →

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

KPRX vs XBIO FAQ

Which is bigger, Kiora Pharmaceuticals or Xenetic Biosciences?

Xenetic Biosciences (XBIO) is larger, with a market capitalization of $3.28M compared with $3.19M for Kiora Pharmaceuticals (KPRX).

Are Kiora Pharmaceuticals and Xenetic Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons